I agree that this site is using cookies. You can find further informations here.
X
Markovets, Aleksandra A.
24  results:
OpenAccess-fulltext X
?
1

Osimertinib + Savolitinib to Overcome Acquired MET-Mediated..:

Hartmaier, Ryan J ; Markovets, Aleksandra A ; Ahn, Myung Ju...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827108/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
2

Candidate mechanisms of acquired resistance to first-line o..:

Chmielecki, Juliann ; Gray, Jhanelle E ; Cheng, Ying...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971254/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
3

Molecular landscape of osimertinib resistance in patients a..:

Lim, Sun Min ; Yang, San-Duk ; Lim, Sangbin...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891830/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
4

The landscape of therapeutic vulnerabilities in EGFR inhibi..:

Criscione, Steven W ; Martin, Matthew J ; Oien, Derek B...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794691/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
5

Targeting melanoma's MCL1 bias unleashes the apoptotic pote..:

Sale, Matthew J ; Minihane, Emma ; Monks, Noel R...
doi:10.17863/CAM.59964.  , 2020
Link: https://doi.org/10.17863..
 
?
6

Mechanisms of Acquired Resistance to Savolitinib, a Selecti..:

Frigault, Melanie M ; Markovets, Aleksandra ; Nuttall, Barrett...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446425/.  , 2020
Link: http://www.ncbi.nlm.nih...
 
?
7

Targeting melanoma's MCL1 bias unleashes the apoptotic pote..:

Sale, Matthew J ; Minihane, Emma ; Monks, Noel R...
doi:10.17863/CAM.47074.  , 2019
Link: https://doi.org/10.17863..
 
?
8

Programmed Cell Death Ligand 1 Expression in Untreated EGFR..:

Brown, Helen ; Vansteenkiste, Johan ; Nakagawa, Kazuhiko...
http://hdl.handle.net/10668/14645.  , 2019
Link: http://hdl.handle.net/10..
 
?
9

Targeting melanoma's MCL1 bias unleashes the apoptotic pote..:

Sale, Matthew J ; Minihane, Emma ; Monks, Noel R...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6856071/.  , 2019
Link: http://www.ncbi.nlm.nih...
 
?
10

Osimertinib as first-line treatment of EGFR mutation-positi..:

Ramalingam, Suresh S ; Yang, James C. -H ; Lee, Chee Khoon...
Journal of Clinical Oncology, Vol.36 No.9, pp.841-849.  , 2018
Link: http://hdl.handle.net/10..
 
?
11

VarDict: a novel and versatile variant caller for next-gene..:

Lai, Zhongwu ; Markovets, Aleksandra ; Ahdesmaki, Miika...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4914105/.  , 2016
Link: http://www.ncbi.nlm.nih...
 
?
12

VarDict: a novel and versatile variant caller for next-gene..:

Lai, Zhongwu ; Markovets, Aleksandra ; Ahdesmaki, Miika...
http://eprints.gla.ac.uk/122577/1/122577.pdf.  , 2016
Link: http://eprints.gla.ac.uk..
 
?
13

Acquired EGFR C797S mediates resistance to AZD9291 in advan..:

Thress, Kenneth S ; Paweletz, Cloud P ; Felip, Enriqueta...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4771182/.  , 2015
Link: http://www.ncbi.nlm.nih...
 
?
14

Acquired resistance to mutant-selective EGFR inhibitor AZD9..:

Eberlein, Catherine A ; Stetson, Daniel ; Markovets, Aleksandra A...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4605607/.  , 2015
Link: http://www.ncbi.nlm.nih...
 
?
15

Analysis of cancer metabolism with high-throughput technolo..:

Herman Damir ; Markovets Aleksandra A
https://doaj.org/toc/1471-2105.  , 2011
Link: https://doi.org/10.1186/..
 
1-15